This study was published in the Journal of the American Medical Association 1998 May 27;279(20):1615-22
Study title and authors:
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Study title and authors:
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.
Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Tex, USA.
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/9613910
Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Tex, USA.
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/9613910
This study investigated the effect of statin treatment on men and women without cardiovascular disease, with average total cholesterol and average low-density lipoprotein cholesterol (LDL) levels and below-average high-density lipoprotein cholesterol (HDL) levels. The study included 5,608 men and 997 women who were given either lovastatin (20-40 mg daily) or placebo and followed for an average of 5.2 years.
The study found that those given the statins had a 4.3% increased risk of death compared to those given the placebo.
